Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes

Inclusion Criteria: * type 1 insulin-dependent diabetic patients in relatively good general condition * non-smoker * body weight \< 80 kg * C-peptide \< 0.03 nmol/l (\<0.09 µg/l) 6 min. after glucagon IV (1mg) (glycemia \> 180 mg/dl) * EBV antibody positive * cooperative and reliable patient giving informed consent by signature; the patient should be informed in sufficient detail on the content and procedure of the protocol, indicating potential risks of intervention and of immunosuppressive therapy; the patient should also be informed that withdrawal of immunosuppressive therapy in patients with persistent plasma C-peptide positivity may result in subsequent loss of ß-cell graft function; the ß cell implant should be identified as a clinical trial Exclusion Criteria: * history of thrombosis or pulmonary embolism * abnormal liver function * HLA antibodies